News Related to Kodiak Sciences

Related coverage linked through entity extraction aliases.

Biotech Stocks Rally on Clinical and Regulatory Catalysts: Ocugen, Kodiak, CytoDyn

Jun 09, 2026

Biotech stocks Ocugen, Kodiak Sciences, and CytoDyn are experiencing market movements driven by clinical data and regulatory milestones, particularly Biologics License Application (BLA) filings. Ocugen saw a surge in short interest, Kodiak reached a 52-week high on positive trial results, and CytoDyn's stock remains volatile as it advances its monoclonal antibody pipeline.

Kodiak Sciences' Eye Drug Zenkuda Succeeds in Late-Stage Diabetic Retinopathy Study

Mar 26, 2026

Kodiak Sciences' experimental drug Zenkuda achieved 62.5% response rate in diabetic retinopathy trial with 85% reduction in sight-threatening complications. The company plans to accelerate FDA submission while preparing for wet AMD study readout in Q3 2026. Shares surged 68.6% following the positive late-stage results.